Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.63 |
| ▸ | MAOB | P27338 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18897097 | 0.81 | MAOA (0.63) | MAOAMAOBMAPTSMN1; SMN2TDP1 | |
| SCHEMBL1638869 | 0.81 | MAOA (0.63) | MAOAMAOBMAP2K1KCNH2 | |
| SCHEMBL12015997 | 0.81 | MAOA (0.68) | MAOAMAOBMAPTTDP1MAP2K1 | |
| SCHEMBL1681280 | 0.81 | MAOA (0.63) | MAOAMAOBMAPTSMN1; SMN2TDP1 | |
| SCHEMBL1639044 | 0.81 | MAOA (0.63) | MAOAMAOBMAPTSMN1; SMN2TDP1 | |
| SCHEMBL1636929 | 0.81 | MAOB (0.63) | MAOAMAOBKDM1AKCNH2 | |
| SCHEMBL3360991 | 0.81 | MAPT (0.43) | MAOAMAOBMAPTSMN1; SMN2TDP1 | |
| Hydrochloric Acid SCHEMBL2436215 | 0.79 | MAOB (0.61) | MAOAMAOBKDM1AKCNH2 | |
| SCHEMBL27510458 | 0.79 | MAOA (0.59) | MAOAMAOBMAP2K1 | |
| SCHEMBL3213057 | 0.78 | MAOA (0.58) | MAOAMAOBMAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021120890-A1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| US-9662337-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-05-30 | — | — | US | disclosed |
| EP-3054947-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| EP-2590954-B1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2016-04-13 | — | — | EP | disclosed |
| US-9273017-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2016-03-01 | — | — | US | disclosed |
| US-9227960-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2016-01-05 | — | — | US | disclosed |
| US-20150239857-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2015-08-27 | — | — | US | disclosed |
| US-20150191457-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2015-07-09 | — | — | US | disclosed |
| US-9045441-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2015-06-02 | — | — | US | disclosed |
| US-9029371-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-05-12 | — | — | US | disclosed |
| WO-2015054038-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
| EP-2473490-B1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| US-20130203745-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| EP-2590954-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-05-15 | — | — | EP | disclosed |
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2012-08-30 | — | — | US | disclosed |
| EP-2473490-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | Abbott Healthcare Products B.V. (NL) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012004375-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011023795-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239857-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | MAOA 2570/4885MAOB 1641/4885MAPT 3767/4885 |
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | MAOA 2836/4885MAOB 1842/4885MAPT 4129/4885 |
| US-20130203745-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | MAOA 2518/4885MAOB 1390/4885MAPT 3719/4885 |
| US-20150191457-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | MAOA 2692/4885MAOB 1690/4885MAPT 3989/4885 |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | MAOA 3762/4885MAOB 3022/4885MAPT 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.